general
In CML, Future Directions Include TKI Sequencing Strategies and Mutational Profiles
Daniel DeAngelo, MD, PhD, discusses how TKIs have given patients with CML a full lifespan and what is being done to build on the incredible progress in this setting.
A key development in modern CML care is the growing achievement of treatment-free remission (TFR). Approximately 25% to 30% of patients who achieve deep, sustained molecular responses can safely discontinue TKI therapy without disease relapse, which ... [1259 chars]
Read Full ArticleShare this story
Up next
Related Stories
‘Paid Rs 40,000 rent, EMI for years’: Noida buyer wins compensation for delayed flat
The Indian Express
500 detained in Delhi protest against CEC Gyanesh Kumar
The Indian Express
Tigress released in Bengal’s Buxa Tiger Reserve; plans afoot for three more by end of year
The Hindu
Digger: Tom Cruise leans into one of his career’s most remarkable performances with glee
The Indian Express
Can no longer accept 'wrong policies': Ex-Rajasthan Minister Vishvendra Singh quits Congress
The Hindu